{"id":783612,"date":"2023-09-12T19:49:00","date_gmt":"2023-09-12T23:49:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-announces-upcoming-investor-webinar-with-leading-key-opinion-leaders-to-discuss-xen1101-and-major-depressive-disorder\/"},"modified":"2023-09-12T19:49:00","modified_gmt":"2023-09-12T23:49:00","slug":"xenon-pharmaceuticals-announces-upcoming-investor-webinar-with-leading-key-opinion-leaders-to-discuss-xen1101-and-major-depressive-disorder","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-announces-upcoming-investor-webinar-with-leading-key-opinion-leaders-to-discuss-xen1101-and-major-depressive-disorder\/","title":{"rendered":"Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders\u00a0to Discuss XEN1101 and Major Depressive Disorder"},"content":{"rendered":"

\nLive broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET
\n<\/h2>\n
\n

VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an investor webinar with two leading key opinion leaders (KOLs) focused on major depressive disorder.<\/p>\n\n\n\n\n\n\n\n
\n Webinar<\/strong>:<\/td>\n\u201cXEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs\u201d<\/td>\n<\/tr>\n
\n Date<\/strong>:<\/td>\nTuesday, September 19, 2023<\/td>\n<\/tr>\n
\n Time<\/strong>:<\/td>\n11:30 am \u2013 1 pm ET Eastern Time (8:30 am \u2013 11 am Pacific Time)<\/td>\n<\/tr>\n
\n Link<\/strong>:<\/td>\nParticipants can register and access the webinar on the Investors<\/a> section of Xenon\u2019s website.<\/td>\n<\/tr>\n
\n Format<\/strong>:<\/td>\nQuestions may be submitted (via chat function) during the live webinar or submitted in advance via email<\/a>.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Speakers include:<\/p>\n